Mobiosense Corp.
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
Mobiosense Corp. currently manufactures and has clinically validated the "Mobiosense™ COVID-19 Isothermal Nucleic Acid Detection Kit" and the "MuTest™ African Swine Fever Detection Kit". The core technology of these products is isothermal nucleic acid amplification. Specifically, by utilizing a unique primer design and polymerase in the formulation, the nucleic acid amplification reaction can occur at a constant temperature. This characteristic allows the technology to overcome the limitation of polymerase chain reaction (PCR), which requires repeated thermal cycling. Furthermore, reverse transcription can be performed simultaneously during the nucleic acid amplification reaction, enabling a more diverse range of compatible downstream detection methods.
The content above was translated by Ai
Founded Year
2015
Unified Business No.
24950178
Status
Active
Number of Employees
4
Total Paid-in
Capital
12,700,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
